This fact, the study authors write, is what has been slowing down the investigative efforts into finding treatments for MERS. So researchers from Regeneron Pharmaceuticals used a piece of technology called VelociGene to engineer the virus so that it affects mice. After infecting a few mice to figure out which antibodies they made to ward off the disease, the researchers put the virus into another type of modeling technology called VelocImmune, a mouse model that spits out human antibodies when infected. When the researchers tested the resulting human antibodies on the original virus in the lab, they found them to be extremely effective. And, interestingly, when mice were given antibodies to fight the mouse equivalent of the virus one day before being infected, the antibodies prevented the virus from replicating—the researchers found less of the virus' RNA in the mice's lungs, indicating that their level of infection would be much less severe.